NOVAVAX, INC. (NASDAQ:NVAX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
First Quarter Financial Results
On May 8, 2017, Novavax, Inc. (the Company) issued a press
release announcing the Companys financial results for the quarter
ended March 31, 2017. A copy of this press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in Items 2.02 and 9.01 of this Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act
except as expressly set forth by specific reference in such a
filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
| Exhibit No. | Description | ||
| 99.1 |
Press release, dated May 8, 2017, regarding the Companys financial results for the quarter ended March 31, 2017. |
||
About NOVAVAX, INC. (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS). NOVAVAX, INC. (NASDAQ:NVAX) Recent Trading Information
NOVAVAX, INC. (NASDAQ:NVAX) closed its last trading session up +0.115 at 0.849 with 4,546,253 shares trading hands.